vs
EXACT SCIENCES CORP（EXAS）与简柏特（G）财务数据对比。点击上方公司名可切换其他公司
简柏特的季度营收约是EXACT SCIENCES CORP的1.5倍（$1.3B vs $878.4M），简柏特净利率更高（10.8% vs -9.8%，领先20.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 5.6%），简柏特自由现金流更多（$269.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 8.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
简柏特是全球领先的信息技术服务、咨询及外包提供商，总部位于美国纽约，最初成立于印度古尔冈，法定注册地为百慕大。集团现有员工超12.5万名，服务覆盖全球30多个国家，于纽交所上市，2023年总营收达44.8亿美元。
EXAS vs G — 直观对比
营收规模更大
G
是对方的1.5倍
$878.4M
营收增速更快
EXAS
高出17.5%
5.6%
净利率更高
G
高出20.6%
-9.8%
自由现金流更多
G
多$148.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.3B |
| 净利润 | $-86.0M | $143.1M |
| 毛利率 | 70.1% | 36.6% |
| 营业利润率 | -9.4% | 14.8% |
| 净利率 | -9.8% | 10.8% |
| 营收同比 | 23.1% | 5.6% |
| 净利润同比 | 90.1% | 0.8% |
| 每股收益（稀释后） | $-0.45 | $0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASG
| Q4 25 | $878.4M | $1.3B | ||
| Q3 25 | $850.7M | $1.3B | ||
| Q2 25 | $811.1M | $1.3B | ||
| Q1 25 | $706.8M | $1.2B | ||
| Q4 24 | $713.4M | $1.2B | ||
| Q3 24 | $708.7M | $1.2B | ||
| Q2 24 | $699.3M | $1.2B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASG
| Q4 25 | $-86.0M | $143.1M | ||
| Q3 25 | $-19.6M | $145.8M | ||
| Q2 25 | $-1.2M | $132.7M | ||
| Q1 25 | $-101.2M | $130.9M | ||
| Q4 24 | $-864.6M | $141.9M | ||
| Q3 24 | $-38.2M | $132.8M | ||
| Q2 24 | $-15.8M | $122.0M | ||
| Q1 24 | $-110.2M | $116.9M |
毛利率EXASG
| Q4 25 | 70.1% | 36.6% | ||
| Q3 25 | 68.6% | 36.4% | ||
| Q2 25 | 69.3% | 35.9% | ||
| Q1 25 | 70.8% | 35.3% | ||
| Q4 24 | 69.0% | 35.7% | ||
| Q3 24 | 69.4% | 35.6% | ||
| Q2 24 | 69.8% | 35.4% | ||
| Q1 24 | 70.0% | 35.0% |
营业利润率EXASG
| Q4 25 | -9.4% | 14.8% | ||
| Q3 25 | -3.0% | 14.8% | ||
| Q2 25 | -0.3% | 14.3% | ||
| Q1 25 | -13.6% | 15.1% | ||
| Q4 24 | -122.8% | 15.2% | ||
| Q3 24 | -5.6% | 15.0% | ||
| Q2 24 | -3.8% | 14.5% | ||
| Q1 24 | -16.7% | 14.1% |
净利率EXASG
| Q4 25 | -9.8% | 10.8% | ||
| Q3 25 | -2.3% | 11.3% | ||
| Q2 25 | -0.1% | 10.6% | ||
| Q1 25 | -14.3% | 10.8% | ||
| Q4 24 | -121.2% | 11.4% | ||
| Q3 24 | -5.4% | 11.0% | ||
| Q2 24 | -2.3% | 10.4% | ||
| Q1 24 | -17.3% | 10.3% |
每股收益（稀释后）EXASG
| Q4 25 | $-0.45 | $0.82 | ||
| Q3 25 | $-0.10 | $0.83 | ||
| Q2 25 | $-0.01 | $0.75 | ||
| Q1 25 | $-0.54 | $0.73 | ||
| Q4 24 | $-4.69 | $0.80 | ||
| Q3 24 | $-0.21 | $0.74 | ||
| Q2 24 | $-0.09 | $0.67 | ||
| Q1 24 | $-0.60 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.2B |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $2.4B | $2.5B |
| 总资产 | $5.9B | $5.8B |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资EXASG
| Q4 25 | $964.7M | $1.2B | ||
| Q3 25 | $1.0B | $740.8M | ||
| Q2 25 | $858.4M | $663.3M | ||
| Q1 25 | $786.2M | $561.6M | ||
| Q4 24 | $1.0B | $671.6M | ||
| Q3 24 | $1.0B | $1.0B | ||
| Q2 24 | $946.8M | $914.2M | ||
| Q1 24 | $652.1M | $478.4M |
总债务EXASG
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.2B |
股东权益EXASG
| Q4 25 | $2.4B | $2.5B | ||
| Q3 25 | $2.5B | $2.5B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.4B | $2.4B | ||
| Q3 24 | $3.2B | $2.4B | ||
| Q2 24 | $3.2B | $2.3B | ||
| Q1 24 | $3.1B | $2.3B |
总资产EXASG
| Q4 25 | $5.9B | $5.8B | ||
| Q3 25 | $5.9B | $5.4B | ||
| Q2 25 | $5.8B | $5.3B | ||
| Q1 25 | $5.7B | $4.9B | ||
| Q4 24 | $5.9B | $5.0B | ||
| Q3 24 | $6.7B | $5.3B | ||
| Q2 24 | $6.7B | $5.2B | ||
| Q1 24 | $6.4B | $4.7B |
负债/权益比EXASG
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $286.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $269.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 20.4% |
| 资本支出强度资本支出/营收 | 3.6% | 1.3% |
| 现金转化率经营现金流/净利润 | — | 2.00× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $734.7M |
8季度趋势，按日历期对齐
经营现金流EXASG
| Q4 25 | $151.7M | $286.7M | ||
| Q3 25 | $219.9M | $308.4M | ||
| Q2 25 | $89.0M | $177.4M | ||
| Q1 25 | $30.8M | $40.4M | ||
| Q4 24 | $47.1M | $203.2M | ||
| Q3 24 | $138.7M | $228.5M | ||
| Q2 24 | $107.1M | $209.3M | ||
| Q1 24 | $-82.3M | $-25.6M |
自由现金流EXASG
| Q4 25 | $120.4M | $269.0M | ||
| Q3 25 | $190.0M | $292.0M | ||
| Q2 25 | $46.7M | $155.1M | ||
| Q1 25 | $-365.0K | $18.5M | ||
| Q4 24 | $10.7M | $183.5M | ||
| Q3 24 | $112.6M | $208.7M | ||
| Q2 24 | $71.2M | $190.0M | ||
| Q1 24 | $-120.0M | $-49.6M |
自由现金流率EXASG
| Q4 25 | 13.7% | 20.4% | ||
| Q3 25 | 22.3% | 22.6% | ||
| Q2 25 | 5.8% | 12.4% | ||
| Q1 25 | -0.1% | 1.5% | ||
| Q4 24 | 1.5% | 14.7% | ||
| Q3 24 | 15.9% | 17.2% | ||
| Q2 24 | 10.2% | 16.2% | ||
| Q1 24 | -18.8% | -4.4% |
资本支出强度EXASG
| Q4 25 | 3.6% | 1.3% | ||
| Q3 25 | 3.5% | 1.3% | ||
| Q2 25 | 5.2% | 1.8% | ||
| Q1 25 | 4.4% | 1.8% | ||
| Q4 24 | 5.1% | 1.6% | ||
| Q3 24 | 3.7% | 1.6% | ||
| Q2 24 | 5.1% | 1.6% | ||
| Q1 24 | 5.9% | 2.1% |
现金转化率EXASG
| Q4 25 | — | 2.00× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | — | 1.34× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 1.43× | ||
| Q3 24 | — | 1.72× | ||
| Q2 24 | — | 1.72× | ||
| Q1 24 | — | -0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
G
| High Tech And Manufacturing | $525.3M | 40% |
| Consumer And Healthcare | $445.8M | 34% |
| Financial Services | $348.2M | 26% |
